# A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

> **NCT05362058** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 928 (actual)

## Conditions studied

- Diabetes
- Type 2 Diabetes

## Interventions

- **DRUG:** Insulin Efsitora Alfa
- **DRUG:** Insulin Degludec

## Key facts

- **NCT ID:** NCT05362058
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-03
- **Primary completion:** 2024-04-10
- **Final completion:** 2024-04-10
- **Target enrollment:** 928 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05362058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05362058, "A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05362058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*